Home About Us People Prof. Dr. med. Kirsten Minden
Paediatric Rheumatology
Prof. Dr. med. Kirsten Minden

Paediatric Rheumatology

Prof. Dr. med. Kirsten Minden

German Rheumatism Research Centre
Epidemiology Unit
Charitéplatz 1
10117 Berlin
Phone: +49 (0)30 28460-669 Fax: +49 (0)30 28460-626 minden@drfz.de

Scientific career and Key Publications

Wissenschaftlicher Werdegang
Seit 2015 Professorin für Versorgungsforschung in der Rheumatologie an der Charité Universitätsmedizin Berlin und am Deutschen Rheuma-Forschungszentrum Berlin
2012 Habilitation
Seit 2001 Wissenschaftlerin am DRFZ, Programmbereich Epidemiologie, seit 2009 Leiterin der Arbeitsgruppe Kinderrheumatologie und Versorgungsforschung
Seit 2006 Kinderrheumatologin im Sozialpädiatrischen Zentrum des Charité Centrums 17 für Frauen-, Kinder- und Jugendmedizin mit Perinatalzentrum und Humangenetik
2003-2006 Oberärztin der Abteilung Kinder- und Jugendrheumatologie des Helios-Klinikums Berlin-Buch
1997-2003 Fachärztin in der Abteilung Kinderrheumatologie des HELIOS-Klinikums Berlin-Buch
1992-1996 Assistenzärztin in der II. Klinik für Kinderheilkunde und Jugendmedizin des Klinikums Berlin-Buch
1990-1992 Ärztin im Praktikum in der II. Klinik für Kinderheilkunde und Jugendmedizin des Klinikums Berlin-Buch
1989 Promotion (Klinik für Orthopädie, Charité Universitätsmedizin Berlin)
1985 Diplom der Medizin (Institut für Anatomie, Charité Universitätsmedizin Berlin)
Education
2006 Additional qualification paediatric rheumatology
2001 Intensive Course in Applied Epidemiology, ARC Epidemiology, University of Manchester, Great Britain
1996 Specialist for paediatrics and adolescent medicine
1992 Approbation
1982-1990 Study of human medicine; Charité University Medicine Berlin
Committee work
Since 2017 Board member of the Initiative für das rheumakranke Kind
Since 2015 Member of the scientific advisory board of the Journal of Rheumatology
Since 2014 Speaker of the working group Transition of the Society for Pediatric Rheumatology
Since 2011 Member of the scientific advisory board of the Journal arthritis+rheuma, from 2011-2019 head of the section paediatric rheumatology
Since 2005 Speaker of the Commission Care and Quality Assurance of the Society for Pediatric Rheumatology
2004-2017 Board member of the Society for Pediatric Rheumatology
Memberships

• German Network for Healthcare Research (DNVF
• German Society for Rheumatology (DGRh)
• German Society for Pediatric Rheumatology (GKJR)
• Paediatric Rheumatology European Society (PReS)
• German Society for Pediatric and Adolescent Medicine (DGKJ)
• Deutsche Rheuma-Liga

Scientific Awards
2013, 2015 Pfizer Research Prize for Rheumatology
2017 Transition Prize of the Society for Transition Medicine
Selected Publications
  1. Minden K, Horneff G, Niewerth M, …, Klotsche J. Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthr Care Res 2019; 71 (4): 471-481.
  2. Sengler C, Zink J, Klotsche J, …, Minden K. Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis – data from a German inception cohort. Arthritis Res Ther 2018; 20(1):276
  3. Listing M, Mönkemöller K, Liedmann I, …, Minden K. The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers – results of the German multicenter inception cohort (ICON). Arthritis Res Ther 2018; 20: 106
  4. Heiligenhaus A, Klotsche J, Tappeiner C, …, Minden K. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study. Rheumatology (Oxford) 2019; 58(6): 975-986.
  5. Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2017 Oct;47(2):269-275.
  6. Klotsche J, Raab A, Niewerth M, …, Minden K. Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German National Pediatric Rheumatological Database from 2000 to 2013. Arthritis Rheumatol 2016 Dec;68(12):3023-3034.
  7. Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855-61.
  8. Sengler C, Klotsche J, Niewerth M, … , Minden K. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open. 2015 Dec 8;1(1):e000074.
  9. Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with juvenile idiopathic arthritis (JIA) treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 2012;51:1407-15.
  10. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K; German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007;46:1015-9.
Minden lab
How can we optimize the care of young people with rheumatism?